Interferon alpha-2
(MIXCUJKCXRNYFM-UHFFFAOYSA-M)
Structure
- SMILES
- IC(S(=O)(=O)[O-])I.CCCN(C(=O)n1cncc1)CCOc1c(Cl)cc(cc1Cl)Cl.[Na+]
- Molecular Formula:
- C16H17Cl3I2N3NaO5S
- Molecular Weight:
- 746.546
- Log P:
- 6.3684
- Hydrogen Bond Acceptor:
- 8
- Hydrogen Bond Donor:
- 0
- TPSA:
- 112.94
- CAS Number(s):
- 98530-12-2
Synonym(s)
1.
Interferon alpha-2
2.
IFN-alpha 2
3.
IFN-alpha-2
4.
IFNalpha-2b, Recombinant
5.
Interferon alfa-2a
6.
Interferon alfa-2b
7.
Interferon alpha-2b, Recombinant
8.
Interferon alpha-A
9.
Interferon-alpha 2
10.
Intron A (Interferon)
11.
LeIF A
12.
Reaferon
13.
Recombinant Interferon alpha-2a
14.
Recombinant Interferon alpha-2b
15.
Ro 22-8181
16.
Roferon-A
17.
Sch-30500
18.
Viferon
19.
IFNalpha 2b, Recombinant
20.
Interferon alfa 2a
21.
Interferon alfa 2b
22.
Interferon alpha 2
23.
Interferon alpha 2b, Recombinant
24.
Interferon alpha A
25.
Interferon alpha-2a, Recombinant
26.
Recombinant IFNalpha-2b
27.
Recombinant Interferon alpha 2a
28.
Recombinant Interferon alpha 2b
29.
Ro 22 8181
30.
Ro 228181
31.
Roferon A
32.
RoferonA
33.
Sch 30500
34.
Sch30500
External Link(s)
| MeSH | D000077190 |
| PubChem Compound | 71306834 |
| Therapeutic Target Database | D0P0WV |
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Toxicity to various agents | FAERS: 8 | US FAERS | |
| 2 | Fatigue | FAERS: 6 | US FAERS | |
| 3 | Nausea | FAERS: 6 | US FAERS | |
| 4 | Asthenia | FAERS: 5 | US FAERS | |
| 5 | Vomiting | FAERS: 4 | US FAERS | |
| 6 | Blood creatine phosphokinase increased | FAERS: 3 | US FAERS | |
| 7 | Hepatotoxicity | FAERS: 3 | US FAERS | |
| 8 | Thrombocytopenia | FAERS: 3 | US FAERS | |
| 9 | Weight decreased | FAERS: 3 | US FAERS | |
| 10 | Agitation | FAERS: 2 | US FAERS | |
| 11 | Cutaneous sarcoidosis | FAERS: 2 | US FAERS | |
| 12 | Drug ineffective | FAERS: 2 | US FAERS | |
| 13 | General physical health deterioration | FAERS: 2 | US FAERS | |
| 14 | Leukopenia | FAERS: 2 | US FAERS | |
| 15 | Lymphopenia | FAERS: 2 | US FAERS | |
| 16 | Malignant melanoma stage III | FAERS: 2 | US FAERS | |
| 17 | Malignant neoplasm progression | FAERS: 2 | US FAERS | |
| 18 | Neutropenia | FAERS: 2 | US FAERS | |
| 19 | Abdominal Pain | FAERS: 1 | US FAERS | |
| 20 | Adverse event | FAERS: 1 | US FAERS | |
| 21 | Amylase abnormal | FAERS: 1 | US FAERS | |
| 22 | Anxiety | FAERS: 1 | US FAERS | |
| 23 | Arthralgia | FAERS: 1 | US FAERS | |
| 24 | Blood bilirubin abnormal | FAERS: 1 | US FAERS | |
| 25 | Blood creatinine abnormal | FAERS: 1 | US FAERS | |
| 26 | Cardiotoxicity | FAERS: 1 | US FAERS | |
| 27 | Cellulitis | FAERS: 1 | US FAERS | |
| 28 | Critical Illness | FAERS: 1 | US FAERS | |
| 29 | Disease Progression | FAERS: 1 | US FAERS | |
| 30 | Disease recurrence | FAERS: 1 | US FAERS | |
| 31 | Dizziness | FAERS: 1 | US FAERS | |
| 32 | Epistaxis | FAERS: 1 | US FAERS | |
| 33 | Erythema Multiforme | FAERS: 1 | US FAERS | |
| 34 | Flank Pain | FAERS: 1 | US FAERS | |
| 35 | General symptom | FAERS: 1 | US FAERS | |
| 36 | Headache | FAERS: 1 | US FAERS | |
| 37 | Hepatitis C | FAERS: 1 | US FAERS | |
| 38 | Hypothyroidism | FAERS: 1 | US FAERS | |
| 39 | Hypoxia | FAERS: 1 | US FAERS | |
| 40 | Incorrect route of drug administration | FAERS: 1 | US FAERS | |
| 41 | Infection | FAERS: 1 | US FAERS | |
| 42 | Leukoencephalopathy | FAERS: 1 | US FAERS | |
| 43 | Malaise | FAERS: 1 | US FAERS | |
| 44 | Malignant neoplasm of conjunctiva | FAERS: 1 | US FAERS | |
| 45 | Medication Error | FAERS: 1 | US FAERS | |
| 46 | Memory impairment | FAERS: 1 | US FAERS | |
| 47 | Metabolic acidosis | FAERS: 1 | US FAERS | |
| 48 | Mixed Connective Tissue Disease | FAERS: 1 | US FAERS | |
| 49 | Myalgia | FAERS: 1 | US FAERS | |
| 50 | Myocardial Infarction | FAERS: 1 | US FAERS | |
| 51 | Myoclonic Epilepsy | FAERS: 1 | US FAERS | |
| 52 | Nerve injury | FAERS: 1 | US FAERS | |
| 53 | Neurological decompensation | FAERS: 1 | US FAERS | |
| 54 | Neutrophil count abnormal | FAERS: 1 | US FAERS | |
| 55 | Neutrophil count decreased | FAERS: 1 | US FAERS | |
| 56 | Neutrophil function disorder | FAERS: 1 | US FAERS | |
| 57 | No adverse event | FAERS: 1 | US FAERS | |
| 58 | Obsessive thoughts | FAERS: 1 | US FAERS | |
| 59 | Paradoxical drug reaction | FAERS: 1 | US FAERS | |
| 60 | Pneumonia | FAERS: 1 | US FAERS | |
| 61 | Product tampering | FAERS: 1 | US FAERS | |
| 62 | Pulmonary Hypertension | FAERS: 1 | US FAERS | |
| 63 | Pyoderma Gangrenosum | FAERS: 1 | US FAERS | |
| 64 | Restlessness | FAERS: 1 | US FAERS | |
| 65 | Sarcoidosis | FAERS: 1 | US FAERS | |
| 66 | Sepsis | FAERS: 1 | US FAERS | |
| 67 | Soft Tissue Infection | FAERS: 1 | US FAERS | |
| 68 | Swelling | FAERS: 1 | US FAERS | |
| 69 | Transaminases increased | FAERS: 1 | US FAERS | |
| 70 | White blood cell count abnormal | FAERS: 1 | US FAERS | |
| 71 | White blood cell count decreased | FAERS: 1 | US FAERS | |
| 72 | nervous system disorder | FAERS: 1 | US FAERS | |
| 73 | Pulmonary toxicity | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.